Regeneron Pharmaceuticals vs Boston Scientific
Side-by-side comparison of AI visibility scores, market position, and capabilities
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
Marlborough MA cardiac devices leader (NYSE: BSX) $16.7B FY2024 revenue (+18%); Farapulse PFA ablation fastest-growing EP device, WATCHMAN FLX 70%+ LAAC share, competing with Abbott and Medtronic.
About
Boston Scientific Corporation is a Marlborough, Massachusetts-based global medical device company — publicly traded on the New York Stock Exchange (NYSE: BSX) as an S&P 500 Health Care component — developing and commercializing medical devices for minimally invasive diagnosis and treatment of cardiovascular disease, cardiac rhythm management, electrophysiology, urology, endoscopy, and neuromodulation through approximately 48,000 employees in 130 countries. In fiscal year 2024, Boston Scientific reported revenues of $16.7 billion (+18% year-over-year) — driven by the Farapulse pulsed field ablation (PFA) system for atrial fibrillation treatment, WATCHMAN FLX left atrial appendage closure (LAAC) device, and Rhythmia Ultra high-density cardiac mapping — making Boston Scientific the fastest-growing large-cap medical device company and one of the strongest organic growth stories in healthcare. CEO Mike Mahoney has executed acquisitions and organic R&D investment to build a diverse cardiovascular and electrophysiology portfolio: the 2023 acquisition of Apollo Endosurgery ($615 million, flexible endoscopic stapling for minimally invasive procedures) and the 2022 acquisition of Lumenis (surgical laser systems) expanded Boston Scientific beyond the cardiac core. Boston Scientific's strongest 2024 growth driver — Farapulse (pulsed field ablation) — achieved rapid adoption as a new standard-of-care in atrial fibrillation ablation by delivering shorter procedure times (2-hour PFA versus 4-hour radiofrequency ablation) and improved safety profile compared to traditional thermal ablation methods.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.